Chronic bilateral subthalamic deep brain stimulation in a patient with homozygous deletion in the parkin gene

Mov Disord. 2004 Dec;19(12):1450-2. doi: 10.1002/mds.20250.

Abstract

Chronic subthalamic nucleus deep brain stimulation (STN-DBS) is an efficacious treatment for idiopathic Parkinson's disease (PD) that cannot be further improved by medical therapy. We present a case of an individual with juvenile parkinsonism caused by homozygous deletion of exon 3 in the parkin gene with disabling long-term side-effects from levodopa who underwent bilateral STN neuromodulation. Parkin-linked parkinsonism may show clinical features different from sporadic PD, yet it shares levodopa responsiveness. Because levodopa responsiveness is a predictor of STN-DBS efficacy, we argued that this kind of surgical approach might be efficacious in hereditary parkin-linked juvenile parkinsonism. We evaluated clinical and functional assessment before and 12 months after surgery. The results showed that the Unified Parkinson Disease Rating Scales Motor score improved by 84% in our patient, the levodopa equivalent daily dose medication (LEDD) was reduced by 66%, and, finally, disabling and severe dyskinesias disappeared.

Publication types

  • Case Reports

MeSH terms

  • Antiparkinson Agents / administration & dosage
  • Antiparkinson Agents / adverse effects
  • Deep Brain Stimulation / methods*
  • Disability Evaluation
  • Dose-Response Relationship, Drug
  • Dyskinesia, Drug-Induced / etiology
  • Exons / genetics
  • Female
  • Gene Deletion*
  • Genomic Imprinting
  • Homozygote*
  • Humans
  • Levodopa / administration & dosage
  • Levodopa / adverse effects
  • Male
  • Parkinsonian Disorders / drug therapy
  • Parkinsonian Disorders / genetics*
  • Parkinsonian Disorders / therapy*
  • Polymerase Chain Reaction
  • Severity of Illness Index
  • Subthalamic Nucleus*
  • Ubiquitin-Protein Ligases / genetics*

Substances

  • Antiparkinson Agents
  • Levodopa
  • Ubiquitin-Protein Ligases
  • parkin protein